0000950170-24-005492.txt : 20240118 0000950170-24-005492.hdr.sgml : 20240118 20240118174506 ACCESSION NUMBER: 0000950170-24-005492 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240116 FILED AS OF DATE: 20240118 DATE AS OF CHANGE: 20240118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kulkarni Samarth CENTRAL INDEX KEY: 0001682019 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 24543088 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS AG STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 ownership.xml 4 X0508 4 2024-01-16 0001674416 CRISPR Therapeutics AG CRSP 0001682019 Kulkarni Samarth C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET BOSTON MA 02127 true true false false Chief Executive Officer true Common Shares 2024-01-16 4 M false 20000 19.12 A 207377 D Common Shares 2024-01-16 4 S false 20000 62.5029 D 187377 D Common Shares 200000 I The Kulkarni 2023 GRAT Stock Option (Right to Buy) 19.12 2024-01-16 4 M false 20000 0.00 D 2027-12-01 Common Shares 20000 59582 D 200,000 common shares were recently transferred to The Kulkarni 2023 GRAT. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.2250 to $63.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018. /s/ Elizabeth Ryland Waldinger, attorney-in-fact 2024-01-18